FDG-PET-CT scans as a decision tool for early immunotherapy discontinuation in advanced melanoma
In this MEDtalk Eva Ellebæk, MD at the National Center for Cancer Immune Therapy, Copenhagen University Hospital, gives an answer to the question if we can use routine FDG-PET-CT scans as a decision tool for early immunotherapy discontinuation in advanced melanoma.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
